AU2003271566A1 - Pyrrolopyrazines as kinase inhibitors - Google Patents

Pyrrolopyrazines as kinase inhibitors

Info

Publication number
AU2003271566A1
AU2003271566A1 AU2003271566A AU2003271566A AU2003271566A1 AU 2003271566 A1 AU2003271566 A1 AU 2003271566A1 AU 2003271566 A AU2003271566 A AU 2003271566A AU 2003271566 A AU2003271566 A AU 2003271566A AU 2003271566 A1 AU2003271566 A1 AU 2003271566A1
Authority
AU
Australia
Prior art keywords
pyrrolopyrazines
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271566A
Other languages
English (en)
Other versions
AU2003271566A8 (en
Inventor
Laurent Meijer
Yvette Mettey
Jean-Michel Vierfond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2003271566A8 publication Critical patent/AU2003271566A8/xx
Publication of AU2003271566A1 publication Critical patent/AU2003271566A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003271566A 2002-08-09 2003-08-08 Pyrrolopyrazines as kinase inhibitors Abandoned AU2003271566A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020292019 EP1388541A1 (en) 2002-08-09 2002-08-09 Pyrrolopyrazines as kinase inhibitors
EP02292019.3 2002-08-09
PCT/EP2003/009515 WO2004016614A2 (en) 2002-08-09 2003-08-08 Pyrrolopyrazines as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2003271566A8 AU2003271566A8 (en) 2004-03-03
AU2003271566A1 true AU2003271566A1 (en) 2004-03-03

Family

ID=30129256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271566A Abandoned AU2003271566A1 (en) 2002-08-09 2003-08-08 Pyrrolopyrazines as kinase inhibitors

Country Status (6)

Country Link
US (1) US8106050B2 (https=)
EP (2) EP1388541A1 (https=)
JP (1) JP4780549B2 (https=)
AU (1) AU2003271566A1 (https=)
CA (1) CA2495060C (https=)
WO (1) WO2004016614A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
FR2876377B1 (fr) * 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
FR2876582B1 (fr) * 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
CN101437538A (zh) * 2006-04-28 2009-05-20 宾夕法尼亚州立大学托管会 修饰的腺病毒六邻体蛋白和其应用
US7683060B2 (en) * 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
CA2716928C (en) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
WO2013028952A2 (en) * 2011-08-25 2013-02-28 Rutgers, The State University Of New Jersey Compositions and methods for enhancing lipid production in microalgae via induction of cell cycle arrest
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016190847A1 (en) * 2015-05-26 2016-12-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286860A (en) * 1992-11-12 1994-02-15 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
JPH10501532A (ja) * 1994-06-09 1998-02-10 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
DE69728688T2 (de) * 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
ES2221213T3 (es) * 1997-10-20 2004-12-16 F. Hoffmann-La Roche Ag Inhibidores de kinasa biciclicos.
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
BR9911365A (pt) * 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
CA2344262A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines as kinase inhibitors
DE60026297T2 (de) * 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
OA12514A (en) * 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
HUP0202332A2 (en) 2000-02-05 2002-10-28 Vertex Pharma Pyrazole compositions useful as inhibitors of erk
JP2004503553A (ja) * 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ６，５−縮合二環式複素環
IL152771A0 (en) * 2000-06-26 2003-06-24 Pfizer Prod Inc PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
CA2482991A1 (en) 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
MY137843A (en) 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1560582A4 (en) 2002-10-09 2008-03-12 Scios Inc AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules

Also Published As

Publication number Publication date
CA2495060A1 (en) 2004-02-26
CA2495060C (en) 2012-01-03
AU2003271566A8 (en) 2004-03-03
WO2004016614A2 (en) 2004-02-26
WO2004016614A3 (en) 2004-05-06
JP2006502137A (ja) 2006-01-19
EP1388541A1 (en) 2004-02-11
US8106050B2 (en) 2012-01-31
JP4780549B2 (ja) 2011-09-28
US20080161312A1 (en) 2008-07-03
EP1527077A2 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
AU2003271566A1 (en) Pyrrolopyrazines as kinase inhibitors
AU2003249442A1 (en) Kinase inhibitors
AU2003222055A1 (en) Kinase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003286711A1 (en) Indazolinone compositions useful as kinase inhibitors
AU2003265349A1 (en) Pyrrolotriazine kinase inhibitors
AU2003202263A1 (en) Roh-kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
AU2003299651A1 (en) Tyrosine kinase inhibitors
AU2003237446A1 (en) Pyrazole-derivatives as p38 kinase inhibitors
AU2003259153A1 (en) Substituted triazine kinase inhibitors
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2003255376A1 (en) Piperidine-derivatives as pde4 inhibitors
AU2003245555A1 (en) Sphingosine kinase inhibitors
AU2003298942A1 (en) Tyrosine kinase inhibitors
EP1558609A4 (en) KINASE INHIBITORS
AU2003253880A1 (en) Novel kinases
AU2003254051A1 (en) Pyrazolopyrimidines as kinase inhibitors
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
AU2003261204A1 (en) Pyrazolopyrimidines as kinase inhibitors
AU2002953255A0 (en) Protein kinase inhibitors
AU2003249683A1 (en) Nf-:b inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase